# Excalibur Fund Managers

> Excalibur Fund Managers is a VC fund backing Biotechnology and Medical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 7
- Last investment: Nov 2006
- Lead investor: 43%
- Last updated: Aug 2026
- Website: http://www.excalibur-group.co.uk

Excalibur Fund Managers is a VC fund in London focused on Biotechnology and Medical. Excalibur Fund Managers Limited is a venture capital firm specializing in early, mid, and late stage investments. It seeks to invest in medical sciences, biotechnology, and life sciences sector. The firm prefers to invest in companies that bring human medicines or medical devices to the market. It prefers to invest in the United Kingdom, UnitedStates, and European companies. The firm prefers to be an active investor and seeks to take a seat on the board of directors of its portfolio companies and likes to play a leading role in financing and other strategic events. It was formerly known as Merlin Biosciences Limited. Excalibur Fund Managers Limited was founded in 1996 and is based in London, United Kingdom. It operates as a subsidiary of Excalibur Group Holdings Ltd.

## Contacts

5 contacts available for Excalibur Fund Managers. Shizune tracks 4 team members at Excalibur Fund Managers. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/excalibur-fund-managers?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Medical | 3 | 43% |
| Health Care | 2 | 29% |
| Pharmaceutical | 2 | 29% |
| Beauty | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series C | 2 | 29% |
| Series D | 2 | 29% |
| Series A | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| United Kingdom | 2 | 29% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chris Evans | Group Chairman | 0 | https://shizune.co/investors/profile/chris-evans-3 |
| Chris Evans | Group Chairman | 0 | https://shizune.co/investors/profile/chris-evans-9 |
| Jeremy Curnock Cook | Director | 0 | https://shizune.co/investors/profile/jeremy-curnock-cook |
| Martin Walton | Managing Director | 0 | https://shizune.co/investors/profile/martin-walton |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neurotech | Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases—including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology. | $35M | Series B | Nov 16, 2006 |  |
| Takeda Cambridge | Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology andmetabolic-related diseases. | $13M | Series D | Jul 07, 2006 |  |
| Intercytex Group | Intercytex Group plc, a development stage biotechnology company, engages in the research, development, and commercialization of cell-based therapies for the repair and regeneration of skin and hair. The company, using its integrated cell technology platform, develops living, human cell-based products. Its product programs in development includeVAVELTA, a facial rejuvenation and skin damage repair product, which completed Phase II trials; SHEF-1-Stem Cell Line, which would develop a cure for AMD, the leading cause of blindness in the elderly; ICX-TRC, a hair regeneration product that completed Phase II trials; and ICX-SKN, a skin graft replacement for burns and acute wounds, which completed Phase I trial. The company was founded in 2000 and is headquartered in Cambridge, the United Kingdom. | $15.7M | Series D | Aug 01, 2005 |  |
| Ardana Bioscience | Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annualfunding of £3.8 million. | $32.4M | Series B | Jul 30, 2003 |  |
| Microscience | Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need.Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis ofan expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates. | $36.4M | Series C | Feb 20, 2002 |  |
| Ardana Bioscience | Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annualfunding of £3.8 million. | $20M | Series A | Oct 22, 2001 |  |
| EpiCept Corporation | EpiCept Corporation headquarters are located in Englewood Cliffs, New Jersey, with a subsidiary company, EpiCept GmbH in Munich Germany. This transatlantic presence facilitates access to European technology and markets and enhances financing and liquidity opportunities.EpiCept and its subsidiary are focused on developing novel, effective,safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes. It is envisioned that EpiCept products will have significant market potential. The products are protected by an aggressive patent program. | $13M | Series C | Jan 10, 2001 |  |

7 of 7 investments shown.

## Co-investors
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 2 deals together
- [ABN AMRO Fund](https://shizune.co/investors/profile/abn-amro) — VC Fund, 2 deals together
- [Apax Partners](https://shizune.co/investors/profile/apax-partners) — VC Fund, 2 deals together
- [Avlar BioVentures](https://shizune.co/investors/profile/avlar-bioventures) — VC Fund, 2 deals together
- [Techno Venture Management](https://shizune.co/investors/profile/tvm-techno-venture-management) — VC Fund, 2 deals together
- [Advent Venture Partners](https://shizune.co/investors/profile/advent-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Excalibur Fund Managers invest in?

Excalibur Fund Managers invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Excalibur Fund Managers?

Public channels for Excalibur Fund Managers include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Excalibur Fund Managers?

The team at Excalibur Fund Managers includes Chris Evans (Group Chairman), Chris Evans (Group Chairman) and Jeremy Curnock Cook (Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co